Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
stockMarket

AZERION WARRANTS: Massive 93% Decline In Last 10 Sessions

Loading stream...
(VIANEWS) - AZERION WARRANTS (AEX: AZRNW.AS) experienced a drastic 93.33% decline in the last 10 sessions, falling from €0.15 to €0.01 at 19:59 EST on Saturday. This marked the fifth consecutive session of losses for AZERION WARRANTS. The AEX-Index is also down 0.08% to €733.37, after two consecutive sessions of losses. AZERION WARRANTS's last closing price was €0.01, 0% below its 52-week high of €0.01.

Yearly Analysis

Based on the given information, AZERION WARRANTS's stock is currently trading at €0.01, which is significantly higher than its 52-week high of €0.01. This indicates that the stock has been performing well and has reached new highs in the past year. However, it's important to note that past performance is not indicative of future results, and investors should conduct their own research and analysis before making any investment decisions. More news about AZERION WARRANTS (AZRNW.AS).

Categories

stockMarket

Tags

Stock PriceAZRNW.ASAZERION WARRANTSPrice DownMarket Session NowStock Price DownStock Market NowMarket SessionStock MarketStock
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com